Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endothelin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Bosentan on Exercise Capacity at High Altitude

NCT00432978
View directory record Official record
Conditions
Altitude, Pulmonary Hypertension
Interventions
Bosentan administration
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation

NCT00001624
View directory record Official record
Conditions
Hyperinsulinemia
Interventions
Insulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 1:05 AM EDT
Withdrawn Phase 1 Interventional

The Role of Endothelin in the Supine Hypertension of Autonomic Failure

NCT01119417
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
BQ123, Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

NCT01890135
View directory record Official record
Conditions
Peripheral Arterial Disease, Intermittent Claudication
Interventions
Zibotentan (ZD4054), placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
sparsentan, Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
87
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 73 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 4, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

NCT00796666
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Sitaxsentan and Sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Fountain Valley, California • Gainesville, Florida • Weston, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 4, 2026, 1:05 AM EDT
Active, not recruiting No phase listed Observational

ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis

NCT03404258
View directory record Official record
Conditions
Single-ventricle, Pulmonary Vascular Resistance Abnormality, Superior Cavo-Pulmonary Anastomosis, Endothelin, Metabolomics
Interventions
Research Blood Sampling
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 2 Years
Enrollment
50 participants
Timeline
2018 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

NCT00613691
View directory record Official record
Conditions
Carcinoma
Interventions
SPI-1620
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 4, 2026, 1:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension

NCT00001527
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 1:05 AM EDT
Completed No phase listed Observational

Observational Endothelin and Markers of Cellular Apoptosis In CSF Head Injury

NCT00498498
View directory record Official record
Conditions
Cerebrovascular Trauma, Neurohormones, Cellular Apoptosis, Endothelin System
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Sacramento, California • Torrance, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 4, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01894022
View directory record Official record
Conditions
Hypertension
Interventions
Ambrisentan 5 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 4, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

NCT00120328
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
SPP301
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
2,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

NCT00617669
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ZD4054, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Greenbrae, California • San Diego, California • Norwich, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 4, 2026, 1:05 AM EDT
Completed No phase listed Observational

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

NCT00452283
View directory record Official record
Conditions
Glaucoma, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 4, 2026, 1:05 AM EDT
Withdrawn No phase listed Observational

Pharmacogenomics in Pulmonary Arterial Hypertension

NCT00593905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions
Sitaxsentan, Bosentan, Ambrisentan
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

NCT05570305
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Endothelin in Pulmonary Hypertension

NCT00759408
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BQ-123
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 4, 2026, 1:05 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

NCT04449198
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Resveratrol, Placebo
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

NCT00554229
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
19
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

NCT05373108
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Macitentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 4, 2026, 1:05 AM EDT
Terminated Phase 4 Interventional Results available

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 4, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 4, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional

Tezosentan in Patients With Pulmonary Arterial Hypertension

NCT01094067
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ACT-050089, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 4, 2026, 1:05 AM EDT